Author of

• 32148

  +

  EP1.14 - Targeted Therapy (ID 204)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32200

    +

    EP1.14-41 - Case Series: Lung Neuroendocrine Carcinoma with EGFR Mutation (Now Available) (ID 1589)

    08:00 - 18:00  |  Author(s): Elisna Syahruddin
    • Abstract
    • Slides

    Background
    

    Lung Neuroendocrine Tumor derived from neuroendocrine cells in the lung and could be classified as well differentiated (low-grade typical carcinoids [TCs] and intermediate-grade atypical carcinoids [ACs]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma or SCLC). Little is known about EGFR mutation in LCNET although EGFR mutation were frequently found ( about 40% ) in Indonesia NSCLC population.

    Method
    

    We reviewed 3 cases from our hospital of large cell neuroendocrine tumor ( LCNET) with EGFR mutation testing available. Clinical data and therapeutic responses were retrospectively evaluated.

    Result
    

    Case#1 was a 53 years heavy smoker male with shortness of breath since 6 months, stg 4 T4N3M1a/pericardial effusion, Trans-thoracal Core biopsy showed LCNEC and harboring EGFR mutation in Exon 18 G719S. He was given Gefitinib, but the diseased progressed within 2 months and continued with Platinum based regimen with survival of 9 months.

    Case#2 was a 64 years old heavy smoker male with shortness of breath and chronic fatigue since 6 months, stg IV T3N3M1a, biopsy from neck lymph nodes showed LCNEC and harboring EGFR mutation in Exon 19 INS/DEL. He was given Erlotinib, but the diseased progressed within 2 months and refused to be given chemotherapy, with survival of 5 months since diagnosis.

    Case#3 was a 48 years old Non Smoker male with shortness of breath and chronic cough since 3 months, stg IIIB T4N3M0, biopsy from supraclavicular lymph nodes showed LCNEC and harboring EGFR mutation in Exon 21 L858R and L861Q. The disease remain stable for 13 months with Erlotinib, and followed by platinum based chemotherapy thereafter. He survived 20 months after diagnosis.

    Conclusion
    

    De-novo EGFR mutation were found in LCNEC, but the response of the TKI is variable.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.